Top Page
Jinxin Fertility Group Ltd.
(1951)
Jinxin Fertility Group Ltd. (1951) vs. iShares MSCI Hong Kong ETF (EWH)
Jinxin Fertility Group Ltd. Business Overview & Revenue Model
Jinxin Fertility Group Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.66B | 2.81B | 2.79B | 2.36B | 1.84B | 1.43B |
| Gross Profit | 907.85M | 1.10B | 1.18B | 913.13M | 771.48M | 565.78M |
| EBITDA | 389.14M | 645.06M | 682.02M | 476.21M | 494.08M | 331.91M |
| Net Income | -946.50M | 283.10M | 344.72M | 121.12M | 339.90M | 251.62M |
Balance Sheet | ||||||
| Total Assets | 14.01B | 14.98B | 14.90B | 15.23B | 12.83B | 9.16B |
| Cash, Cash Equivalents and Short-Term Investments | 719.77M | 570.82M | 852.90M | 1.40B | 1.93B | 2.47B |
| Total Debt | 2.92B | 2.71B | 2.55B | 4.16B | 2.09B | 406.87M |
| Total Liabilities | 4.76B | 4.63B | 4.71B | 6.50B | 4.07B | 1.70B |
| Stockholders Equity | 9.19B | 10.27B | 10.09B | 8.64B | 8.55B | 7.28B |
Cash Flow | ||||||
| Free Cash Flow | 338.55M | 489.30M | 510.92M | -417.65M | 263.62M | 41.89M |
| Operating Cash Flow | 513.33M | 629.20M | 684.48M | 541.74M | 343.45M | 308.04M |
| Investing Cash Flow | -434.61M | -293.27M | -375.04M | -1.38B | -1.57B | 1.15B |
| Financing Cash Flow | -95.17M | -458.29M | -950.45M | 460.14M | 955.05M | -55.58M |
Jinxin Fertility Group Ltd. Technical Analysis
Jinxin Fertility Group Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$1.59B | 5.48 | 20.47% | 4.37% | -3.56% | -17.45% | |
66 Neutral | HK$6.61B | 18.11 | 14.86% | 2.55% | 16.41% | 32.97% | |
64 Neutral | HK$8.07B | 16.42 | 6.78% | ― | -13.92% | -36.32% | |
63 Neutral | HK$6.92B | 23.57 | 31.23% | 1.79% | 28.53% | 22.34% | |
55 Neutral | HK$6.59B | -6.32 | -9.67% | 2.50% | -8.56% | -403.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$2.25B | ― | -6.41% | 1.11% | 2.05% | -285.88% |
Jinxin Fertility Group Ltd. Corporate Events
Jinxin Fertility Group Limited announced a slowdown in the decrease of IVF treatment cycles for the nine months ending September 30, 2025, compared to the previous year. The company’s flagship hospital in Chengdu showed significant improvement, while the Shenzhen hospital’s progress was slower due to an upcoming relocation. In the U.S., the delay in implementing a California bill affected treatment cycles, aligning with expectations. The company is confident in its long-term growth prospects, supported by favorable policies and operational improvements.
The most recent analyst rating on (HK:1951) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.
Jinxin Fertility Group Ltd. announced a delay in the dispatch of a circular related to the proposed adoption of the 2025 Share Scheme and conditional grant of options and restricted shares to its directors and senior management. The delay is due to the need for additional time to prepare and finalize the necessary information, with the new dispatch date set on or before November 11, 2025. This postponement may affect the timeline for shareholder engagement and decision-making regarding the share scheme.
The most recent analyst rating on (HK:1951) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.
Jinxin Fertility Group Ltd. has announced a proposed adoption of the 2025 Share Scheme, aiming to align the interests of its directors and key employees with the company’s long-term growth objectives. The scheme includes conditional grants of options and restricted shares to management and non-executive grantees, pending shareholder approval at an upcoming extraordinary general meeting.
The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.80 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.
Jinxin Fertility Group Ltd. announced a change in its board composition with the resignation of Mr. Fang Min as a non-executive director and his replacement by Mr. Shuyun Chen, effective immediately. Mr. Chen brings extensive experience from his previous roles in investment and healthcare sectors, which could enhance the company’s strategic direction and governance.
The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.80 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.
Jinxin Fertility Group Limited has announced the composition of its board of directors and the roles within its various committees. The announcement highlights the leadership structure and the strategic roles assigned to each director, which are crucial for the company’s governance and operational strategy. This organizational update is expected to enhance the company’s decision-making processes and maintain its commitment to medical quality and research and development.
The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.80 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.
Jinxin Fertility Group Limited announced the resignation of Dr. John G. Wilcox from his role as an executive director and member of several board committees, allowing him to focus on the company’s U.S. operations. Dr. Geng Lihong has been appointed to the Medical Quality Control and R&D Committee, signaling a shift in the company’s board composition, which may impact its strategic focus and operational dynamics.
The most recent analyst rating on (HK:1951) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.
Jinxin Fertility Group Limited has announced the composition of its board of directors and their roles within the company. This includes the establishment of five committees, each with specific directors assigned to oversee various aspects of the company’s operations, such as audit and risk management, remuneration, and strategic decisions. This organizational structure is likely to enhance the company’s governance and operational efficiency, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1951) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.
Jinxin Fertility Group Ltd. reported a significant financial downturn for the first half of 2025, with a revenue decrease of 10.7% and a net loss of approximately RMB1,044.1 million, compared to a net profit in the same period of 2024. The company also experienced a substantial decline in non-IFRS adjusted net profit and EBITDA, reflecting challenges in maintaining its financial performance. The board decided against declaring an interim dividend, signaling a cautious approach amid the financial setbacks.
The most recent analyst rating on (HK:1951) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.
Jinxin Fertility Group Ltd. has issued a profit warning, anticipating a loss of up to RMB1,090 million for the first half of 2025, primarily due to impairments and provisions related to its operations in the United States and Laos. Despite these challenges, the company remains confident in its long-term growth prospects, citing strong industry foundations and supportive national policies. Additionally, the company has appointed Mr. Dong Yang as the acting chief financial officer, who will oversee financial management and business development.
The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.33 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.
Jinxin Fertility Group Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. The board is structured with executive, non-executive, and independent non-executive directors, and has established five committees to oversee various aspects of the company’s operations. This announcement underscores the company’s commitment to strong governance and strategic oversight, which is crucial for maintaining its position in the competitive fertility industry.
The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.33 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.
Jinxin Fertility Group Limited has announced a scheduled board meeting on August 25, 2025, to discuss and approve the interim results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, impacting stakeholders and potentially influencing its market positioning.
The most recent analyst rating on (HK:1951) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.